Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer

References

• Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;175(3):889. doi:10.1016/j.cell.2018.10.019.
   PubMed Web of Science ®Google Scholar
• Thysell E, Vidman L, Ylitalo EB, et al. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol. 2019;13(8):1763–1777. doi:10.1002/1878-0261.12526.
   PubMed Web of Science ®Google Scholar
• Ylitalo EB, Thysell E, Jernberg E, et al. Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship Between androgen receptor activity and immune response. Eur Urol. 2017;71(5):776–787. doi:10.1016/j.eururo.2016.07.033.
   PubMed Web of Science ®Google Scholar
• You S, Knudsen BS, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016;76(17):4948–4958. doi:10.1158/0008-5472.CAN-16-0902.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer With prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3(12):1663–1672. doi:10.1001/jamaoncol.2017.0751.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi:10.1056/NEJMoa1503747.
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Rajwa P, Thibault C, et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82(6):584–598. doi:10.1016/j.eururo.2022.08.002.
   PubMed Web of Science ®Google Scholar
• Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high gleason scores. Am J Clin Pathol. 2002;117(3):471–477. doi:10.1309/G6PR-Y774-X738-FG2K.
   PubMed Web of Science ®Google Scholar
• Bonk S, Kluth M, Hube-Magg C, et al. Prognostic and diagnostic role of PSA immunohistochemistry: a tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget. 2019;10(52):5439–5453. doi:10.18632/oncotarget.27145.
   PubMedGoogle Scholar
• Zhao L, Yu N, Guo T, et al. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(6):1047–1054. doi:10.1158/1055-9965.EPI-13-0696.
   PubMed Web of Science ®Google Scholar
• Richardsen E, Andersen S, Al-Saad S, et al. Evaluation of the proliferation marker ki-67 in a large prostatectomy cohort. PLoS One. 2017;12(11):e0186852. doi:10.1371/journal.pone.0186852.
   PubMed Web of Science ®Google Scholar
• Richardsen E, Uglehus RD, Due J, et al. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol. 2010;34(3):316–322. doi:10.1016/j.canep.2010.03.019.
   PubMed Web of Science ®Google Scholar
• Hammarsten P, Josefsson A, Thysell E, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol. 2019;32(9):1310–1319. doi:10.1038/s41379-019-0260-6.
   PubMed Web of Science ®Google Scholar
• Wikstrom P, Bergstrom SH, Josefsson A, et al. Epithelial and stromal characteristics of primary tumors predict the bone metastatic subtype of prostate cancer and patient survival after androgen-deprivation therapy. Cancers. 2022;14(21):5195. doi:10.3390/cancers14215195.
   PubMed Web of Science ®Google Scholar
• Thomas C, Baunacke M, Erb HHH, et al. Systemic triple therapy in metastatic hormone-sensitive prostate cancer (mHSPC): ready for prime time or still to be explored? Cancers. 2021;14(1):8. doi:10.3390/cancers14010008.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803. doi:10.1038/nrd3253.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi:10.1056/NEJMoa1702900.
   PubMed Web of Science ®Google Scholar
• Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235–1248. doi:10.1093/annonc/mdy072.
   PubMed Web of Science ®Google Scholar
• Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605–616. doi:10.1016/j.euo.2022.04.007.
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Lilja H, Falkmer S, et al. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 1988;12(1):39–46. doi:10.1002/pros.2990120106.
   PubMed Web of Science ®Google Scholar
• Erbersdobler A, Isbarn H, Steiner I, et al. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology. 2009;74(5):1169–1173. doi:10.1016/j.urology.2009.02.061.
   PubMed Web of Science ®Google Scholar
• Schlomm T, Iwers L, Kirstein P, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008;21(11):1371–1378. doi:10.1038/modpathol.2008.104.
   PubMed Web of Science ®Google Scholar
• Hamid AA, Huang HC, Wang V, et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021;32(9):1157–1166. doi:10.1016/j.annonc.2021.06.003.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Rydzewski NR, Zhang L, et al. Prognosis associated with luminal and basal subtypes of metastatic prostate cancer. JAMA Oncol. 2021;7(11):1644–1652. doi:10.1001/jamaoncol.2021.3987.
   PubMed Web of Science ®Google Scholar
• Naito Y, Kato M, Kawanishi H, et al. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer. Prostate. 2023;83(4):307–315. doi:10.1002/pros.24462.
   PubMed Web of Science ®Google Scholar
• Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374. doi:10.1038/s41467-017-00393-y.
   PubMedGoogle Scholar
• Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479. doi:10.1126/scisignal.aam7479.
   PubMed Web of Science ®Google Scholar